Nasus Pharma Ltd
NS002
anaphylaxis
Resolved
104days ago
Phase 2 readout · Mar 25, 2026
What's at stake
Phase 2 trial results for NS002 in anaphylaxis are due Mar 25, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 15h ago
“Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen ® ;”